Challenges in Biosimilar Pharmacovigilance
This session of the Biosimilars 2016 will look into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post marketing surveillance issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies and ADR related issues.Biosimilar guidelines for pharmacovigilance practice and pharmacoepidemiology are the points that shall be laid emphasis in this session.
U.S. average annual spending growth from 2002 to 2007 was 16% for biologics, compared with 3.7% for drugs. In same proportion pharmacovigilance for biosimilars has been comparitively more than other pharmaceutical products.
Biosimilar guidelines for pharmacovigilance practice and pharmacoepidemiology are the points that shall be laid emphasis in this session.This session of the Biosimilars 2016 will look into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post marketing surveillance issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies and ADR related issues. Post marketing surveillance is the key concern for biosimilars to be kept under vigilance.
- Current problems in pharmacovigilance
- Role of pharma industries in the improvement of pharmacovigilance system
- Detection and evaluation of drug safety signals
- Adverse drug reactions with pharmaceutical products
- Good pharmacovigilance practice and pharmacoepidemiology
Related Conference of Challenges in Biosimilar Pharmacovigilance
Challenges in Biosimilar Pharmacovigilance Conference Speakers
Recommended Sessions
- Challenges in Biosimilar Pharmacovigilance
- BCS & IVIVC Based Biowaivers
- Bioequivalence Assessment
- Biosimilar Companies and Market Analysis
- Biosimilars Analytical Strategies
- Biosimilars Research Pipeline
- Brexit Effects on Biosimilars
- Clinical Development of Biosimilars
- Current Challenges in Developing Biosimilars
- Emerging Biologics in Therapeutics
- Emerging Biosimilars in Therapeutics
- Entrepreneurs Investment Meet
- Globalization of Biosimilars
- Intellectual Property Rights
- Legal Issues and BPCI ACT
- Plant Produced Biosimilar Products
- Regulatory Approach for Biosimilars